The purpose of this study is to evaluate the safety, pharmacokinetics, anti-tumor activity, and identify a tolerable dose of AMG 228 in subjects with advanced solid tumors.

Inclusion Criteria:

• Subject must have a pathologically documented, definitively diagnosed, advanced solid tumor
• Adequate hematological, renal, hepatic, and coagulation laboratory assessments

Exclusion Criteria:

• Active autoimmune disease, history of autoimmune disease
• Treatment with immune modulators including
• Use of warfarin, factor Xa inhibitors, or direct thrombin inhibitors
• Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 days
• Major surgery within 28 days of study day 1